Biologics in inflammatory bowel disease: what are the data?

United European Gastroenterology Journal

Volumn 3, Issue 5, 2015, Pages 419-428

  Côté Daigneault, Justin ^a,b   Bouin, Mickael ^a   Lahaie, Raymond ^a   Colombel, Jean Frédéric ^b   Poitras, Pierre ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

biologics; clinical trials; Crohn's disease; Inflammatory bowel disease; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; USTEKINUMAB; VEDOLIZUMAB;

CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATORY BOWEL DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 85006184605     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640615590302     Document Type: Review

References (37)

1. B.DerkxJ.TaminiauS.Radema. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet1993; 342: 173–174.
2. H.M.Van DullmenS.J.Van DeventerD.W.Hommes. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology1995; 109: 129–135.
3. S.R.TarganS.B.HanauerS.J.H.Van Deventer. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease. N Engl J Med1997; 337: 1029–1036.
4. M.LémannJ.-Y.MaryB.Duclos. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology2006; 130: 1054–1061.
5. S.B.HanauerB.G.FeaganG.R.Lichtenstein. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002; 359: 1541–1549.
6. P.RutgeertsB.G.FeaganG.R.Lichtenstein. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology2004; 126: 402–413.
7. B.E.SandsF.H.AndersonC.N.Bernstein. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med2004; 350: 876–885.
8. J.F.ColombelW.J.SandbornW.Reinisch. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med2010; 362: 1383–1395.
9. B.G.FeaganJ.W.McDonaldR.Panaccione. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology2014; 146: 681–688.
10. S.B.HanauerW.J.SandbornP.Rutgeerts. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology2006; 130: 323–333.
11. M.WatanabeT.HibiK.G.Lomax. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohn's Colitis2012; 6: 160–173.
12. J.F.ColombelW.J.SandbornP.Rutgeerts. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007; 132: 52–65.
13. P.RutgeertsG.Van AsscheW.J.Sandborn. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012; 142: 1102–1111.
14. C.ReenaersE.LouisJ.Belaiche. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?Aliment Pharmacol Ther2012; 36: 1040–1048.
15. K.IshidaT.InoueK.Fujiwara. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients. World J Gastroenterol2013; 19: 2676–2682.
16. W.J.SandbornP.RutgeertsR.Enns. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med2007; 146: 829–838.
17. W.J.SandbornB.G.FeaganS.Stoinov. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med2007; 357: 228–238.
18. S.SchreiberM.Khaliq-KareemiI.C.Lawrance. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med2007; 357: 239–250.
19. S.SchreiberI.C.LawranceO.Thomsen. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease – subgroup results from a placebo-controlled study. Aliment Pharmacol Ther2011; 33: 185–193.
20. X.HébuterneM.LémannY.Bouhnik. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2012; 62: 201–208.
21. W.J.SandbornM.T.AbreuG.D'Haens. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol2010; 8: 688–695.
22. S.GhoshE.GoldinF.H.Gordon. Natalizumab for active Crohn's disease. N Engl J Med2003; 348: 24–32.
23. W.J.SandbornJ.F.ColombelR.Enns. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med2005; 353: 1912–1925.
24. S.R.TarganB.G.FeaganR.N.Fedorak. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology2007; 132: 1672–1683.
25. W.J.SandbornB.G.FeaganP.Rutgeerts. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med2013; 369: 711–721.
26. B.E.SandsB.G.FeaganP.Rutgeerts. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment had failed. Gastroenterology2014; 147: 618–627.
27. W.J.SandbornC.GasinkL.L.Gao. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med2012; 367: 1519–1528.
28. K.W.SchroederW.J.TremaineD.M.Ilstrup. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med1987; 317: 1625–1629.
29. P.RutgeertsW.J.SandbornB.G.Feagan. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med2005; 353: 2462–2476.
30. R.PanaccioneS.GhoshS.Middleton. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology2014; 146: 392–400.
31. D.LaharieA.BourreilleJ.Branche. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet2012; 380: 1909–1915.
32. W.ReinischW.J.SandbornD.W.Hommes. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut2011; 60: 780–787.
33. W.J.SandbornG.van AsscheW.Reinisch. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology2012; 142: 257–265.
34. Y.SuzukiS.MotoyaH.Hanai. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol2014; 49: 283–294.
35. W.J.SandbornB.G.FeaganC.Marano. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology2014; 146: 85–95.
36. W.J.SandbornB.G.FeaganC.Marano. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology2014; 146: 96–109.
37. B.G.FeaganP.RutgeertsB.E.Sands. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med2013; 369: 699–710.